(Q35193615)

7 August 2017

1 reference

title

Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers (English)

1 reference

7 August 2017

0 references

Gavin D Barlow

1

1 reference

7 August 2017

Donna L Lamping

series ordinal

2

1 reference

7 August 2017

Peter G Davey

series ordinal

3

1 reference

7 August 2017

Dilip Nathwani

series ordinal

4

1 reference

7 August 2017

publication date

1 August 2003

1 reference

Lancet Infectious Diseases

7 August 2017

published in

1 reference

7 August 2017

volume

3

1 reference

7 August 2017

issue

8

1 reference

7 August 2017

page(s)

476-488

1 reference

Community-acquired pneumonia: the annual cost to the National Health Service in the UK.

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

The cost of treating community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Antimicrobial treatment of community acquired pneumonia in adults: A conference report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Quality of care, process, and outcomes in elderly patients with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

1 reference

7 January 2021

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Searching for information on outcomes: do you need to be comprehensive?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Predicting death in patients hospitalized for community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Community acquired pneumonia: aetiology and usefulness of severity criteria on admission

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Patients hospitalized after initial outpatient treatment for community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Implementation of admission decision support for community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Severe community-acquired pneumonia. Assessment of severity criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

1 reference

7 January 2021

Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

The community-acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

1 reference

7 January 2021

Hospital nurse staffing and patient mortality, nurse burnout, and job dissatisfaction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

1 reference

7 January 2021

Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

1 reference

7 January 2021

The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

1 reference

7 January 2021

Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

1 reference

7 January 2021

Quality of life measures in health care. I: Applications and issues in assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Development standards for health measures.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Assessing health status and quality-of-life instruments: attributes and review criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Measuring symptomatic and functional recovery in patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Beyond health outcomes: the advantages of measuring process

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

1 reference

7 January 2021

A statewide initiative to improve the care of hospitalized pneumonia patients: The Connecticut Pneumonia Pathway Project

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Influence of deviation from guidelines on the outcome of community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Effect of Macrolides as Part of Initial Empiric Therapy on Length of Stay in Patients Hospitalized With Community-Acquired Pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

1 reference

7 January 2021

Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

What is meant by intention to treat analysis? Survey of published randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Methods in health service research. Evaluation of health interventions at area and organisation level

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

1 reference

7 January 2021

Systematic reviews of evaluations of prognostic variables

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Temporal trends in outcomes of older patients with pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Segmented regression analysis of interrupted time series studies in medication use research

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

Impact of NICE guidance on laparoscopic surgery for inguinal hernias: analysis of interrupted time series

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900721-7

7 January 2021

10.1016/S1473-3099(03)00721-7

Identifiers

DOI

1 reference

7 August 2017

1 reference